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Aims—To develop a clinical cardiac risk algorithm for stable patients with suspected CAD based 
upon angina typicality and CAD risk factors.
Methods and Results—Between 2004 and 2011, 14,004 adults with suspected CAD referred 
for cardiac imaging were followed: 1) 9,093 patients for CCTA (CCTA-1) followed for 2.0 years; 
2) 2,132 patients for CCTA (CCTA-2) followed for 1·6 years, and 3) 2,779 patients for exercise 
myocardial perfusion scintigraphy followed for 5.0 years. A best-fit model from CCTA-1 for 
prediction of death or myocardial infarction (MI) was developed, with integer values proportional 
to regression coefficients. Discrimination was assessed using C-statistic. The validated model was 
also tested for estimation of the likelihood of obstructive CAD, defined as ≥50% stenosis, as 
compared to method of Diamond and Forrester (D-F).
Primary outcomes included all-cause mortality and non-fatal MI. Secondary outcomes included 
prevalence of angiographically obstructive CAD. In CCTA-1, best-fit model discriminated 
individuals at risk of death or MI (C-statistic 0·76). The integer model ranged from 3-13, and 
corresponded to 3-year death risk or MI of 0·25% to 53·8%. When applied to the CCTA-2 and 
MPS, the model demonstrated C-statistics of 0·71 and 0·77. Both best-fit (C=0·76, 95% CI 
0·746-0·771) and integer model (C=0·71, 95% CI 0·693-0·719) performed better than D-F 
(C=0·64; 95% CI, 0·628-0·659) for estimating obstructive CAD.
Conclusions—For stable symptomatic patients with suspected CAD, we developed a history-
based method for prediction of death and obstructive CAD.
Keywords
Coronary artery disease; prognosis; diagnosis
INTRODUCTION
Medical history-based assessment of symptomatic stable patients with suspected coronary 
artery disease (CAD) has relied upon estimating the likelihood of obstructive CAD rather 
than the risk of clinical events, such as death or myocardial infarction (MI) (1-5). Recent 
data have challenged these diagnostic algorithms, and suggest that they overestimate the 
prevalence of obstructive CAD in patients referred for non-invasive and invasive testing 
(6-8). The absence of a well-validated pre-test method for determining risk of CAD events, 
as well as an accurate method for estimating the likelihood of obstructive CAD, may evoke 
overutilization of testing for individuals at low risk for incident clinical events or obstructive 
CAD (9). We sought to determine whether information acquired through medical history 
taking alone could predict risk of myocardial infarction or death and obstructive CAD in 
symptomatic stable individuals with suspected CAD.
METHODS
Study Participants
This study consisted of 3 distinct non-overlapping cohorts of symptomatic stable individuals 
with suspected but without prior history of CAD who were referred for non-invasive cardiac 
imaging between 2004-2011: 1) a development cohort of 9,093 patients from 8 centers and 6 
countries referred for coronary CT angiography (CCTA-1) followed for death or MI; 2) a 
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CCTA validation cohort of 2,132 patients from 4 centers and 4 countries referred for CCTA 
(CCTA-2) followed for death or MI; and 3) a validation cohort of 2,779 patients from 1 
center referred for exercise stress myocardial perfusion scintigraphy (MPS) followed for 
death.
The CCTA-1 derivation cohort comprised patients referred for CCTA from Phase I of the 
CONFIRM registry (Coronary CT Angiography EvaluatioN For Clinical Outcomes: An 
InteRnational Multicenter Registry), which has been previously described (10). Among 12 
participating sites, 4 were excluded due to lack of information related to symptoms or 
follow-up data for non-fatal MI, leaving 17,226 patients from 8 sites in 6 countries that 
constituted the derivation dataset for the clinical model. Sites included 3 from the United 
States (N=5727), and 1 each from Canada (N=2171), Germany (N=1785), Italy (N=1895), 
South Korea (N=4912), and Switzerland (N=736). In sequential order, we excluded patients 
with prior coronary revascularization or MI (n=1110); who were asymptomatic (n=4389); 
who did not have complete symptom and/or CAD risk factor collection (n=1959); who were 
referred for imaging from the emergency department or inpatient setting (n=604); or who 
were lost to follow-up (n=71). After exclusions, 9,093 patients comprised the final study 
dataset. The median follow-up time for CCTA-1 was 2.0 years (Interquartile Range [IQR] = 
1.4 to 3.1 years).
The CCTA-2 validation cohort consisted of patients from Phase II of CONFIRM, detailing 
identical elements to Phase I CONFIRM and prospectively designed specifically to serve as 
a validation dataset to Phase I CONFIRM findings (10). Among the 5 participating sites, 1 
was excluded due to lack of follow-up information for MI, resulting in 3,996 patients from 
the United States (N=1016), Canada (N=636), South Korea (N=1404) and Austria (N=940). 
In sequential order, we excluded patients with prior coronary revascularization or MI 
(n=250); who were asymptomatic (n=1072); who did not have complete symptom and/or 
CAD risk factor collection (n=542); who were referred for imaging from the emergency 
department or inpatient setting (n=0); or who were lost to follow-up (n=0). 2,132 patients 
comprised the dataset, and are herein referred to as CCTA-2. The median follow-up time for 
CCTA-2 was 1·6 years (IQR = 0·8 to 2·8 years).
The MPS validation cohort was referred for exercise myocardial perfusion scintigraphy 
(MPS) at the Cedars-Sinai Medical Center and followed for all-cause mortality. Excluded 
patients include those undergoing prior coronary revascularization or MI or who underwent 
pharmacologic stress testing (n=6405); who were asymptomatic (n=1095); who did not have 
complete symptom and/or CAD risk factor collection (n=425); who were referred for 
imaging from the emergency department or inpatient hospital setting (n=1903); or who were 
lost to follow-up (n=0). 2,779 comprised the final study dataset and are herein referred to as 
the MPS validation cohort. The median follow-up time for MPS was 5·0 years (IQR 3·5 to 
6·4 years).
Coronary Artery Disease Risk Factor and Symptom Type
Prior to testing, we performed medical histories to ascertain the presence of categorical 
CAD risk factors, which were defined in accordance to accepted guidelines. Hypertension 
was defined by a history of blood pressure of ≥140/90 mmHg and/or treatment with anti-
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hypertensive medications (11). Diabetes mellitus was defined by a fasting glucose of 126 
mg/dl or greater and/or use of insulin or oral hypoglycemic agents (12). Dyslipidemia was 
defined in accordance with National Cholesterol Education Program Adult Treatment Panel 
III guidelines or by treatment with lipid lowering medication (13). Current smoking status 
was defined by active smoking within 3 months of presentation. Family history of CAD was 
defined as MI or cardiac death in a first-degree relative (14).
Symptoms were ascertained through interview by a physician or health professional, or by 
written questionnaire. Chest pain was categorized according to criteria for angina pectoris 
(3, 15). Patients with typical angina experienced substernal jaw, and/or arm pressure-like 
pain that occurred with exertion and resolved within 15 minutes of rest and/or use of 
nitroglycerin. Patients with atypical angina experienced 2 of these characteristics. Patients 
with non-anginal chest pain experienced 1 or none of these characteristics. Dyspneic patients 
without chest pain were categorized as having typical angina, in accordance to their 
prognostic risk (16). From these data, the pre-test likelihood of obstructive CAD was 
calculated by the method of Diamond and Forrester (3).
Follow-up and Event Ascertainment
All study individuals for CCTA-1 and CCTA-2 were followed for an endpoint of death or 
non-fatal myocardial infarction, and for an endpoint of death for MPS. Follow-up 
procedures were approved by all study centers’ institutional review boards. Death status for 
non-US centers was gathered by clinical visits, telephone contacts and questionnaires sent 
by mail; with verification of all reported events by hospital records or direct contact with a 
patient’s attending physician. Death status for US centers was ascertained by query of the 
Social Security Death Index or by scripted in-person or phone interview by an experienced 
physician and/or nurse study investigator.
General Statistical Analyses
Categorical variables are displayed as frequencies and percents, while, continuous variables 
are described as mean ± standard deviations, or medians with interquartile ranges. Variables 
were compared with chi-squared statistic for categorical variables and by Student’s unpaired 
t-test or Wilcoxon non-parametric test where appropriate for continuous variables. A two-
tailed p value <0.05 was considered statistically significant. Analyses were conducted using 
SAS version 9.2 (SAS Institute, www.sas.com, Cary, NC).
Development of a Medical History-Based Model for Adverse Clinical Events
Information from the CCTA-1 cohort was used to develop a clinical prediction model for 
death or MI (CCTA-1) or death (MPS) based on CAD risk factors and symptom type. The 
best overall clinical prediction algorithm was fit using Cox proportional hazards models. 
Eight variables were evaluated for risk prediction, and were restricted to those that could be 
easily obtained from a standard cardiac medical history: age, gender, diabetes, hypertension, 
dyslipidemia, family history of CAD, current smoking status and symptom type. Symptom 
type was categorized dichotomously in accordance to prognostic relevance for individuals 
referred for non-invasive imaging as typical angina or dyspnea versus atypical angina or 
non-anginal pain (16). The final best-fit Cox model was selected by applying backwards 
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stepwise regression, examining the - 2loglikelihood, and minimizing Bayes’ Information 
Criterion (BIC) (17). Interactions between age and all risk factors were examined.
Once variables were selected for the final Cox model, an integer-based model was 
developed to predict the 3-year probability of death or MI. The integer-based model was 
created by transformation of the Cox regression coefficients from the best-fit model. To 
maximize ease of use, risk score values were scaled and transposed such that age points 
related to the decade of a patient’s age (e.g., a 5 for patients aged 50-59) and each CAD risk 
factor present added an additional point to the total score.
Validation of the Medical History-Based Model
External validation was conducted for the best-fit model using the CCTA-2 and MPS 
cohorts. For comparison, a best-fit Cox regression model was constructed based on the same 
candidate variables as in the CCTA-1 model but using data from the validation cohorts. 
Similar to the CCTA-1 model, backwards stepwise regression was used to create the final 
best-fit model. For MPS, we adjusted the predicted risk based upon ratio of risk of death to 
risk of death or MI from the CCTA-1 best-fit model. The accuracy of the CCTA-1 best-fit 
model was examined using discrimination and calibration. Discrimination was evaluated by 
C-statistic, while calibration was described by Nam and D’Agostino’s modification of the 
Hosmer-Lemeshow goodness of fit procedures (18). We further examined discrimination 
and calibration of the integer-based model (Table 1). Observed versus predicted risk was 
computed based on categories defined by deciles of predicted risk, and compared by plotting 
predicted and actual event rates within each decile.
Discrimination of the Medical History-Based Model for Obstructive Coronary Artery 
Disease
We evaluated the ability of the integer-based risk model to discriminate between individuals 
with and without obstructive CAD, as defined by a ≥50% luminal diameter stenosis in any 
coronary artery ≥1·5 mm in diameter. Obstructive CAD was determined from CCTAs from 
the CCTA-1 and CCTA-2 cohorts, but was not available within the MPS validation cohort. 
CCTAs were performed and interpreted by Level III experts in an intent-to-diagnose fashion 
(19, 20).
We applied the integer-based model from CCTA-1 to estimate the probability of obstructive 
CAD in CCTA-2. For obstructive CAD, the area under the receiver operator characteristics 
curve of the integer-based model was directly compared to the method of Diamond and 
Forrester. Further, we used the aggregate data from CCTA-1 and CCTA-2 to determine the 
rate of obstructive CAD by integer values from the developed model.
RESULTS
Clinical Characteristics of the Study Cohorts
Baseline characteristics of the CCTA-1 development and CCTA-2 and MPS validation 
cohorts are listed in Table 2. During follow-up, 65 deaths and 155 MIs occurred in the 
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CCTA-1 cohort, while 14 deaths and 90 MIs occurred in the CCTA-2 validation cohort. In 
the MPS validation cohort, 51 deaths occurred during follow-up.
Clinical Prediction Model Derivation
In univariate Cox regression applied to CCTA-1, several CAD risk factors and symptom 
type predicted risk of death or MI (Appendix). Despite its lack of significance in univariate 
models, gender was forced into multivariate models given its accepted clinical importance. 
As no significant interactions were identified, the final best-fit Cox model for prediction of 
death or MI included age, gender, symptom type, diabetes, hypertension, family history of 
CAD and smoking status. The BIC value for the best-fit Cox model was 3554·4, which 
represented a substantial improvement over the null model BIC of 3716.6. The β 
coefficients, standard errors, hazard ratios and p-values for each of the covariates in the best-
fit Cox model are shown in Table 3. The C-statistic for this model was 0·76.
Discrimination and Calibration of the Medical History-Based Prediction Model
Table 4 presents the C-statistics for the best-fit and integer-based Cox model for the 
CCTA-1, CCTA-2 and MPS validation cohorts. For MPS, for which only death was 
available during follow-up, probabilities were determined by multiplication of the risk of 
death or MI by 0·405, which represented the ratio of the 3-year risk of death (1·17%) to the 
3-year risk of death or MI (2·89%) in CCTA-1. Discrimination of the best-fit model 
performed well in both CCTA-2 and MPS, achieving similar discrimination to the CCTA-1 
best-fit model. Figure 1 presents the decile plots for assessment of calibration of the 
CCTA-1 model. Integer models were based upon covariates categorized in binary fashion 
except for age, which was categorized by range as 18-39 years, 40-49 years, 50-59 years, 
60-69 years, and ≥70 years (Table 1).
Integer scores were calculated by the following formula: Total points = [Age 40-49 years = 
4; 50-59 years = 5; 60-69 years = 6; ≥70 years = 7) + Gender (1=male, 0=female) + Diabetes 
(1=diabetic; 0=non-diabetic) + Hypertension (1=hypertensive; 0=normotensive) + Family 
history of CAD (1=yes, 2=no).
Discrimination of the Medical History-Based Model for Estimating the Likelihood of 
Obstructive Coronary Artery Disease
The AUC of the best-fit CCTA-1 model (0·76; 95% CI 0·746 to 0·771) was higher than the 
Diamond-Forrester (0·64; 95% CI 0·628 to 0·659) methods for discriminating individuals 
with versus without obstructive CAD (p<0·0001). Across the range of integer values, the 
likelihood of obstructive CAD ranged from 0 to 82·4% (Table 5).
DISCUSSION
We developed and validated a method for identifying stable individuals with suspected CAD 
who are at risk of death or myocardial infarction. Our aim was to create a parsimonious 
model that incorporates CAD factors that can be derived solely from a medical history. We 
demonstrated the effectiveness of this method for measures of risk stratification, 
discrimination, and calibration. Further, the model exhibited superior discriminatory 
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performance when tested against the Diamond-Forrester method for determining pre-test 
likelihood of obstructive CAD.
One potential function of this model may be to serve as an effective “gatekeeper” to identify 
individuals who are at sufficiently low risk of incident death or MI that the yield from 
further testing may be low. At present, more than 10 million CAD imaging tests are 
performed annually in the United States alone at high direct and indirect costs, with rates of 
test normalcy significantly higher today as compared to only a decade ago (9,21). As an 
example, in the largest CCTA study to date, more than 42% of individuals were identified as 
having no CAD (22). Similarly, the rates of test normalcy for MPS have dramatically 
increased over time, with a prevalence of >90% in a study of 39,515 patients (21).
In this study, those with an integer value ≤7—which represented nearly half of the study 
population—only 1·0% experienced an adverse clinical event, and only 10% of these 
individuals possessed obstructive CAD. These findings may convey a greater sense of 
prognostic and diagnostic certainty towards avoidance of testing for individuals whose risk 
and prevalence of disease is sufficiently low to preclude the need for further evaluation. 
Conversely, this model may be used to identify individuals whose risk is high, and who may 
benefit from further testing. While representing only 3% of the combined cohort, 9% of 
individuals with an integer score >9 experienced an event and 54% possessed obstructive 
CAD. The need for testing is apparent in this group, and in accordance with societal 
guidance documents (23).
To date, no robust medical history-based prediction model has been available for identifying 
stable symptomatic patients at risk for death or MI. In its absence, clinicians have relied 
upon estimates of the likelihood of an individual possessing obstructive CAD (3). These 
methods have served as the cornerstone for assessment of patients with suspected CAD for 
the last 40 years. Nevertheless, these methods were validated against invasive angiographic 
and pathologic correlates; and their application demonstrates a 3-fold overestimation of 
CAD in patients referred for non-invasive imaging that suggests the need for contemporary 
revision (6). In the present study, the developed medical history-based model was superior 
to the Diamond-Forrester method for discrimination of individuals with versus without 
obstructive anatomic CAD. In this regard, this model may serve a dual role not only as a 
prognostic instrument but also as a diagnostic tool.
This study is not without limitations. We studied patients referred for CCTA and exercise 
MPS—given their common performance and similarities for indications considered 
appropriate for use—with our study findings robustly applicable to both modalities (24,25). 
Yet, whether the model can be employed for patients being considered for exercise treadmill 
testing, other imaging tests, or in patients not considered for any testing remains unknown. 
Second, patient-reported histories may have resulted in ascertainment bias, and CAD risk 
factor profiles may have been more accurate with adjunctive confirmation by vital sign or 
laboratory values. One advantage of the present study is the applicability to practicing 
physicians who routinely solicit histories in the office setting. Third, the prediction model 
included all-cause rather than cardiac-specific death. In doing so, this study is 
disencumbered from information bias but may result in reduced prognostic specificity. 
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Finally, we examined stable symptomatic individuals referred for outpatient imaging, and 
caution should be taken to apply the model to patients in the emergency department or 
inpatient setting.
CONCLUSIONS
We developed and validated a simple medical-history based method that predicts risk of 
death and myocardial infarction in symptomatic stable patients with suspected CAD. 
Further, this method exhibits superior performance to traditional methods for identifying 
individuals with obstructive CAD.
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ABBREVIATIONS
CAD coronary artery disease
MPS myocardial perfusion scintigraphy
MI Myocardial infarction
CCTA coronary CT angiography
D-F Diamond and Forrester
CONFIRM Coronary CT Angiography EvaluatioN For Clinical Outcomes: An 
InteRnational Multicenter Registry
BIC Bayes’ Information Criterion
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TRANSLATIONAL PERSPECTIVE
A simple and easy-to-develop model derived solely from a patients’ medical history is 
useful in identifying stable individuals with suspected CAD who are at risk of death or 
myocardial infarction. This history-based model may potentially serve a useful purpose 
as an effective “gatekeeper” towards avoidance of testing for individuals whose risk and 
prevalence of disease is sufficiently low to preclude the need for further evaluation. 
Conversely, this model may be used to identify individuals whose risk is high, and who 
may benefit from further testing.
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Figure 1. 
Calibration Plots for (A) CCTA-1 Development, (B) CCTA-2 Validation and (C) MPS 
Validation Cohort
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